Adaptive radiotherapy versus standard radiotherapy in head-neck cancer patients

Comparison of Weekly Adaptive Radiotherapy and Standard Volumetric Modulated Arc Therapy: Impact on Salivary Function and Quality of Life in Head and Neck Cancer Patients - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/05/109891

Enrollment

Registered

2026-05-04

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C148- Malignant neoplasm of overlappingsites of lip, oral cavity and pharynx

Interventions

Intervention1: adaptive radiotherapy: offline weekly adaptive radiation in head and neck cancer patients under going radiation for a duration of 7 weeks Control Intervention1: Standard radiotheray: St

Eligibility

Inclusion criteria

Inclusion criteria: Squamous cell carcinoma head and neck histologically proven, T3 and T4 or N0 and N3. Performance Status ECOG less than 2 Biological parameters compatible with concomitant treatment Written informed consent

Exclusion criteria

Exclusion criteria: Previous Induction chemotherapy previously treated with chemo or RT Early stage (T1, T2 ,N0) Surgery (with curative intent) before radiotherapy Both parotids included in target volume ECOG PS greater than 3 History of other malignancy in head and neck region within the last 5 years Not eligible for concomitant chemotherapy treatment

Design outcomes

Primary

Measure	Time frame
To assess salivary function and quality of life scores in weekly adaptive radiotherapy group and standard radiotherapy group at baseline, 3 and 6 months after radiotherapy.Timepoint: At baseline,3 and 6 months.	—

Secondary

Measure	Time frame
To compare incidence of dysphagia in weekly adaptive radiotherapy group and standard radiotherapy group at baseline, 3 & 6 months after radiotherapyTimepoint: At baseline,3 & 6 months;To assess locoregional control in weekly adaptive radiotherapy group and standard radiotherapy group at baseline, 3 & 6 months after radiotherapy. To assess Speech Function in weekly adaptive radiotherapy group & standard radiotherapy group at baseline, 3 & 6 months after radiotherapy. To assess the acute & late toxicities in weekly adaptive radiotherapy group and standard radiotherapy group at baseline, 3 & 6 months after radiotherapy.Timepoint: At baseline,3 & 6 months	—

Measure

Time frame

To compare incidence of dysphagia in weekly adaptive radiotherapy group and standard radiotherapy group at baseline, 3 & 6 months after radiotherapyTimepoint: At baseline,3 & 6 months;To assess locoregional control in weekly adaptive radiotherapy group and standard radiotherapy group at baseline, 3 & 6 months after radiotherapy. To assess Speech Function in weekly adaptive radiotherapy group & standard radiotherapy group at baseline, 3 & 6 months after radiotherapy. To assess the acute & late toxicities in weekly adaptive radiotherapy group and standard radiotherapy group at baseline, 3 & 6 months after radiotherapy.Timepoint: At baseline,3 & 6 months

—

Countries

India

Contacts

Public ContactRadha Krishna Kamineni

AIIMS JAMMU

shabab.angurana@aiimsjammu.edu.in7298005679

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026